Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Steel, Helen C ^a   Theron, Annette J ^a   Cockeran, Riana ^a   Anderson, Ronald ^a   Feldman, Charles ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ASTHMA; BACTERIAL INFECTION; BIOFILM; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CELL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; TARGET CELL; ANIMAL; DRUG EFFECT; PHAGOCYTE;

BACTERIA (MICROORGANISMS);

ADAPTIVE IMMUNITY; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNITY, INNATE; MACROLIDES; PHAGOCYTES;

EID: 84863690101     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/584262     Document Type: Review

References (244)

1. Wikipedia, the free encyclopedia,. Macrolide, 2011, http://en.wikipedia. org/wiki/Macrolide
2. Zuckerman J. M., Qamar F., Bono B. R., Review of macrolides (azithromycin, clarithromycin), ketolides (telithromycin) and glycylcyclines (tigecycline) Medical Clinics of North America 2011 95 4 761 791
3. Foulds G., Shepard R. M., Johnson R. B., The pharmacokinetics of azithromycin in human serum and tissues Journal of Antimicrobial Chemotherapy 1990 25 supplement 73 82 (Pubitemid 20043952)
4. Fraschini F., Scaglione F., Pintucci G., Maccarinelli G., Dugnani S., Demartini G., The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans Journal of Antimicrobial Chemotherapy 1991 27 61 65
5. Zuckerman J. M., Macrolides and ketolides: azithromycin, clarithromycin, telithromycin Infectious Disease Clinics of North America 2004 18 3 621 649 (Pubitemid 39089098)
6. Mandell G. L., Delivery of antibiotics by phagocytes Clinical Infectious Diseases 1994 19 5 922 925 (Pubitemid 24368832)
7. Tenson T., Lovmar M., Ehrenberg M., The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome Journal of Molecular Biology 2003 330 5 1005 1014 (Pubitemid 36818898)
8. Kaiser G., Protein synthesis inhibitors: macrolides mechanism of action animation. Classification of agents Pharmamotion. The Community College of Baltimore County, 2011, http://en.wikipedia.org/wiki/Proteinsynthesisinhibitor
9. Marriott H. M., Mitchell T. J., Dockrell D. H., Pneumolysin: a double-edged sword during the host-pathogen interaction Current Molecular Medicine 2008 8 6 497 509
10. Tsujimoto H., Ono S., Efron P. A., Scumpia P. O., Moldawer L. L., Mochizuki H., Role of toll-like receptors in the development of sepsis Shock 2008 29 3 315 321 (Pubitemid 351271701)
11. Takeuchi O., Akira S., Pattern recognition receptors and inflammation Cell 2010 140 6 805 820
12. Kimmitt P. T., Harwood C. R., Barer M. R., Induction of type 2 Shiga toxin synthesis in Escherichia coli 0157 by 4-quinolones The Lancet 1999 353 9164 1588 1589 (Pubitemid 29219214)
13. Murakami J., Kishi K., Hirai K., Hiramatsu K., Yamasaki T., Nasu M., Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro International Journal of Antimicrobial Agents 2000 15 2 103 109 (Pubitemid 30347250)
14. Wong C. S., Jelacic S., Habeeb R. L., Watkins S. L., Tarr P. I., The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections New England Journal of Medicine 2000 342 26 1930 1936 (Pubitemid 30419087)
15. Stevens D. L., Ma Y., Salmi D. B., McIndoo E., Wallace R. J., Bryant A. E., Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus Journal of Infectious Diseases 2007 195 2 202 211 (Pubitemid 46080052)
16. Dumitrescu O., Badiou C., Bes M., Reverdy M. E., Vandenesch F., Etienne J., Lina G., Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain Clinical Microbiology and Infection 2008 14 4 384 388 (Pubitemid 351356532)
17. Serna A. IV, Boedeker E. C., Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections Current Opinion in Gastroenterology 2008 24 1 38 47 (Pubitemid 350190896)
18. McGannon C. M., Fuller C. A., Weiss A. A., Different classes of antibiotics differentially influence shiga toxin production Antimicrobial Agents and Chemotherapy 2010 54 9 3790 3798
19. Spreer A., Kerstan H., Bttcher T., Gerber J., Siemer A., Zysk G., Mitchell T. J., Eiffert H., Nau R., Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone Antimicrobial Agents and Chemotherapy 2003 47 8 2649 2654 (Pubitemid 36919474)
20. Bttcher T., Ren H., Goiny M., Gerber J., Lykkesfeldt J., Kuhn U., Lotz M., Bunkowski S., Werner C., Schau I., Spreer A., Christen S., Nau R., Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone Journal of Neurochemistry 2004 91 6 1450 1460 (Pubitemid 39658571)
21. Karlstrm A., Boyd K. L., English B. K., McCullers J. A., Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza Journal of Infectious Diseases 2009 199 3 311 319
22. Spreer A., Lugert R., Stoltefaut V., Hoecht A., Eiffert H., Nau R., Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis Critical Care Medicine 2009 37 7 2253 2258
23. Anderson R., Steel H. C., Cockeran R., Smith A. M., von Gottberg A., de Gouveia L., Brink A., Klugman K. P., Mitchell T. J., Feldman C., Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy 2007 59 2 224 229 (Pubitemid 47072061)
24. Anderson R., Steel H. C., Cockeran R., von Gottberg A., de Gouveia L., Klugman K. P., Mitchell T. J., Feldman C., Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro Journal of Antimicrobial Chemotherapy 2007 60 5 1155 1158 (Pubitemid 47617770)
25. Hirst R. A., Mohammed B. J., Mitchell T. J., Andrew P. W., O'Callaghan C., Streptococcus pneumoniae -induced inhibition of rat ependymal cilia is attenuated by antipneumolysin antibody Infection and Immunity 2004 72 11 6694 6698 (Pubitemid 39425455)
26. Lagrou K., Peetermans W. E., Jorissen M., Verhaegen J., Van Damme J., Van Eldere J., Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro Journal of Antimicrobial Chemotherapy 2000 46 5 717 723
27. Fukuda Y., Yanagihara K., Higashiyama Y., Miyazaki Y., Hirakata Y., Mukae H., Tomono K., Mizuta Y., Tsukamoto K., Kohno S., Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae European Respiratory Journal 2006 27 5 1020 1025 (Pubitemid 44911118)
28. Cockeran R., Steel H. C., Wolter N., Effects of clarithromycin at sub-minimum inhibitory concentrations on early ermB gene expression, metabolic activity and growth of an ermB -expressing, macrolide-resistant strain of Streptococcus pneumoniae Open Journal of Respiratory Diseases 2012 2 1 8
29. Yasuda Y., Kasahara K., Mizuno F., Nishi K., Mikasa K., Kita E., Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model Antimicrobial Agents and Chemotherapy 2007 51 5 1741 1752 (Pubitemid 46744154)
30. Nakamura S., Yanagihara K., Araki N., Yamada K., Morinaga Y., Izumikawa K., Seki M., Kakeya H., Yamamoto Y., Kamihira S., Kohno S., Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice Antimicrobial Agents and Chemotherapy 2010 54 2 757 762
31. Bui K. Q., Banevicius M. A., Nightingale C. H., Quintiliani R., Nicolau D. P., In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa Journal of Antimicrobial Chemotherapy 2000 45 1 57 62 (Pubitemid 30060234)
32. Tanaka G., Shigeta M., Komatsuzawa H., Sugai M., Suginaka H., Usui T., Effect of clarithromycin on Pseudomonas aeruginosa biofilms Chemotherapy 2000 46 1 36 42 (Pubitemid 30009332)
33. Tateda K., Standiford T. J., Pechere J. C., Yamaguchi K., Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors Current Pharmaceutical Design 2004 10 25 3055 3065 (Pubitemid 39242901)
34. Wozniak D. J., Keyser R., Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa Chest 2004 125 2, supplement 12 62S 69S (Pubitemid 38200962)
35. Hall-Stoodley L., Stoodley P., Evolving concepts in biofilm infections Cellular Microbiology 2009 11 7 1034 1043
36. Nalca Y., Jnsch L., Bredenbruch F., Geffers R., Buer J., Hussler S., Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach Antimicrobial Agents and Chemotherapy 2006 50 5 1680 1688
37. Bala A., Kumar R., Harjai K., Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections Journal of Medical Microbiology 2011 60 3 300 306
38. Cai Y., Chai D., Wang R., Bai N., Liang B. B., Liu Y., Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review Journal of Antimicrobial Chemotherapy 2011 66 5 968 978
39. Renna M., Schaffner C., Brown K., Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection Journal of Clinical Investigation 2011 121 9 3554 3563
40. Oishi K., Sonoda F., Kobayashi S., Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases Infectious Immunology 1994 62 10 4145 4152 (Pubitemid 24301936)
41. Vanaudenaerde B. M., Wuyts W. A., Geudens N., Dupont L. J., Schoofs K., Smeets S., Van Raemdonck D. E., Verleden G. M., Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells American Journal of Transplantation 2007 7 1 76 82 (Pubitemid 44952858)
42. Brennan S., Cooper D., Sly P. D., Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin Thorax 2001 56 1 62 64 (Pubitemid 32041721)
43. Yamaryo T., Oishi K., Yoshimine H., Tsuchihashi Y., Matsushima K., Nagatake T., Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages Antimicrobial Agents and Chemotherapy 2003 47 1 48 53 (Pubitemid 36070341)
44. Hodge S., Hodge G., Jersmann H., Matthews G., Ahern J., Holmes M., Reynolds P. N., Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease American Journal of Respiratory and Critical Care Medicine 2008 178 2 139 148 (Pubitemid 351957772)
45. Kita E., Sawaki M., Nishikawa F., Mikasa K., Yagyu Y., Takeuchi S., Yasui K., Narita N., Kashiba S., Enhanced interleukin production after long-term administration of erythromycin stearate Pharmacology 1990 41 4 177 183
46. Kamemoto A., Ara T., Hattori T., Fujinami Y., Imamura Y., Wang P. L., Macrolide antibiotics like azithromycin increase lipopolysaccharide-induced IL-8 production by human gingival fibroblasts European Journal of Medical Research 2009 14 7 309 314
47. Bailly S., Pocidalo J. J., Fay M., Gougerot-Pocidalo M. A., Differential modulation of cytokine production by macrolides: interleukin-6 production is increased by spiramycin and erythromycin Antimicrobial Agents and Chemotherapy 1991 35 10 2016 2019
48. Konno S. I., Adachi M., Asano K., Kawazoe T., Okamoto K. I., Takahashi T., Influences of roxithromycin on cell-mediated immune responses Life Sciences 1992 51 10 PL107 PL112
49. Suzaki H., Asano K., Ohki S., Kanai K., Mizutani T., Hisamitsu T., Suppressive activity of a macrolide antibiotic, roxithromycin, on pro- inflammatory cytokine production in vitro and in vivo Mediators of Inflammation 1999 8 4-5 199 204 (Pubitemid 30019329)
50. Yamasawa H., Oshikawa K., Ohno S., Sugiyama Y., Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release American Journal of Respiratory Cell and Molecular Biology 2004 30 4 569 575 (Pubitemid 38457190)
51. Bosnar M., Bonjak B., ui S., Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1 beta Journal of Pharmacology Experimental Therapy 2009 331 1 104 113
52. Meyer M., Huaux F., Gavilanes X., Van Den Brle S., Lebecque P., Lo Re S., Lison D., Scholte B., Wallemacq P., Leal T., Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis American Journal of Respiratory Cell and Molecular Biology 2009 41 5 590 602
53. Abe S., Nakamura H., Inoue S., Takeda H., Saito H., Kato S., Mukaida N., Matsushima K., Tomoike H., Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells American Journal of Respiratory Cell and Molecular Biology 2000 22 1 51 60 (Pubitemid 30342959)
54. Kikuchi T., Hagiwara K., Honda Y., Gomi K., Kobayashi T., Takahashi H., Tokue Y., Watanabe A., Nukiwa T., Clarithromycin suppresses lipopolysaccharide- induced interleukin-8 production by human monocytes through AP-1 and NF- B transcription factors Journal of Antimicrobial Chemotherapy 2002 49 5 745 755 (Pubitemid 34537634)
55. Desaki M., Okazaki H., Sunazuka T., Omura S., Yamamoto K., Takizawa H., Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation Antimicrobial Agents and Chemotherapy 2004 48 5 1581 1585 (Pubitemid 38544362)
56. Shinkai M., Foster G. H., Rubin B. K., Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells American Journal of Physiology 2006 290 1 L75 L85
57. Shinkai M., Tamaoki J., Kobayashi H., Kanoh S., Motoyoshi K., Kute T., Rubin B. K., Clarithromycin delays progression of bronchial epithelial cells from G 1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression Antimicrobial Agents and Chemotherapy 2006 50 5 1738 1744
58. Cigana C., Assael B. M., Melotti P., Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells Antimicrobial Agents and Chemotherapy 2007 51 3 975 981 (Pubitemid 46355283)
59. Bosnar M., ui S., Bonjak B., Nuji K., Ergovi G., Marjanovi N., Paali I., Hrvai B., Polanec D., Glojnari I., Haber V. E., Azithromycin inhibits macrophage interleukin-1 production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia International Immunopharmacology 2011 11 4 424 434
60. Otsu K., Ishinaga H., Suzuki S., Effects of a novel nonantibiotic macrolide, EM900, on cytokine and mucin gene expression in a human airway epithelial cell line Pharmacology 2009 88 5-6 3272 332
61. Hoffmann E., Dittrich-Breiholz O., Holtmann H., Kracht M., Multiple control of interleukin-8 gene expression Journal of Leukocyte Biology 2002 72 5 847 855 (Pubitemid 35365158)
62. Cigana C., Nicolis E., Pasetto M., Assael B. M., Melotti P., Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells Biochemical and Biophysical Research Communications 2006 350 4 977 982 (Pubitemid 44584188)
63. Shinkai M., Henke M. O., Rubin B. K., Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action Pharmacology and Therapeutics 2008 117 3 393 405
64. Ikegaya S., Inai K., Iwasaki H., Naiki H., Ueda T., Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway Journal of Chemotherapy 2009 21 4 396 402
65. Yamauchi K., Shibata Y., Kimura T., Abe S., Inoue S., Osaka D., Sato M., Igarashi A., Kubota I., Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon- stimulated macrophages International Journal of Biological Sciences 2009 5 7 667 678
66. Reato G., Cuffini A. M., Tullio V., Mandras N., Roana J., Banche G., Foa R., Carlone N. A., Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils International Journal of Antimicrobial Agents 2004 23 2 150 154 (Pubitemid 38175396)
67. Parnham M. J., Culi O., Erakovi V., Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment European Journal of Pharmacology 2005 517 1-2 132 143 (Pubitemid 40916224)
68. Tamaoki J., Kadota J., Takizawa H., Clinical implications of the immunomodulatory effects of macrolides The American Journal of Medicine 2004 117 supplement 9 5S 11S
69. Feldman C., Anderson R., Rubin B. K., Tamaoki J., The cytoprotective interactions of antibiotics with human ciliated airway epithelium Antibiotics as Anti-Inflammatory and Immunomodulatory Agents 2005 Basel, Switzerland Birkhauser 49 63
70. Oda H., Kadota J. I., Kohno S., Hara K., Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis Chest 1995 108 1 116 122
71. Hashimoto N., Kawabe T., Hara T., Imaizumi K., Wakayama H., Saito H., Shimokata K., Hasegawa Y., Effect of erythromycin on matrix metalloproteinase-9 and cell migration Journal of Laboratory and Clinical Medicine 2001 137 3 176 183 (Pubitemid 32203197)
72. Kanai K., Asano K., Hisamitsu T., Suzaki H., Suppresion in matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro European Respiratory Journal 2004 23 5 671 678 (Pubitemid 38618134)
73. Kanai K. I., Asano K., Hisamitsu T., Suzaki H., Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro Mediators of Inflammation 2004 13 5-6 313 319 (Pubitemid 40018364)
74. Yasutomi M., Ohshima Y., Omata N., Yamada A., Iwasaki H., Urasaki Y., Mayumi M., Erythromycin differentially inhibits lipopolysaccharide- or poly(I:C)-induced but not peptidoglycan-induced activation of human monocyte-derived dendritic cells Journal of Immunology 2005 175 12 8069 8076 (Pubitemid 41798369)
75. Park J. Y., Kim Y. H., Ja Y. L., Kyung H. K., Myung K. J., Jin H. L., Jae Y. Y., Dong S. H., Joon S. H., Macrolide-affected Toll-like receptor 4 expression from Helicobacter pylori -infected monocytes does not modify interleukin-8 production FEMS Immunology and Medical Microbiology 2005 44 2 171 176 (Pubitemid 41373373)
76. Mitsuyama T., Tanaka T., Hidaka K., Abe M., Hara N., Inhibition by erythromycin of superoxide anion production by human polymorphonuclear leukocytes through the action of cyclic AMP-dependent protein kinase Respiration 1995 62 5 269 273
77. Anderson R., Theron A. J., Feldman C., Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils Inflammation 1996 20 6 693 705 (Pubitemid 27036184)
78. Montenez J. P., Van Bambeke F., Piret J., Brasseur R., Tulkens P. M., Mingeot-Leclercq M. P., Interactions of macrolide antibiotics (erythromycin A, roxithromycin, erythromycylamine [dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models Toxicology and Applied Pharmacology 1999 156 2 129 140 (Pubitemid 29196576)
79. Muni V., Banjanac M., Kotrun S., Nuji K., Bosnar M., Marjanovi N., Rali J., Matijai M., Hlevnjak M., Haber V. E., Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis Pharmacological Research 2011 64 3 298 307
80. Tamaoki J., Kondo M., Kohri K., Aoshiba K., Tagaya E., Nagai A., Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages Journal of Immunology 1999 163 5 2909 2915 (Pubitemid 29399222)
81. Asano K., Kamakazu K., Hisamitsu T., Suzaki H., Suppressive activity of macrolide antibiotics on nitric oxide production from nasal polyp fibroblasts in vitro Acta Oto-Laryngologica 2003 123 9 1064 1069 (Pubitemid 38021523)
82. Anderson R., Tintinger G., Cockeran R., Potjo M., Feldman C., Beneficial and harmful interactions of antibiotics with microbial pathogens and the host innate immune system Pharmaceuticals 2010 3 5 1694 1710
83. Takeyama K., Tamaoki J., Chiyotani A., Tagaya E., Konno K., Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in-vitro Journal of Pharmacy and Pharmacology 1993 45 8 756 758 (Pubitemid 23258698)
84. Feldman C., Anderson R., Non-antimicrobial activity of macrolides: therapeutic potential in chronic inflammatory airway disorders South African Journal of Epidemiology Infections 2009 24 4 21 26
85. Shimizu T., Shimizu S., Hattori R., Gabazza E. C., Majima Y., In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells American Journal of Respiratory and Critical Care Medicine 2003 168 5 581 587 (Pubitemid 37088602)
86. Ribeiro C. M. P., Hurd H., Wu Y., Martino M. E. B., Jones L., Brighton B., Boucher R. C., O'Neal W. K., Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia PLoS ONE 2009 4 6
87. Tanabe T., Kanoh S., Tsushima K., Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells American Journal of Respiratory Cell and Molecular Biology 2011 45 5 1075 1083
88. Imamura Y., Yanagihara K., Mizuta Y., Seki M., Ohno H., Higashiyama Y., Miyazaki Y., Tsukamoto K., Hirakata Y., Tomono K., Kadota J. I., Kohno S., Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-oxododecanoyl) homoserine lactone in NCI-H292 cells Antimicrobial Agents and Chemotherapy 2004 48 9 3457 3461 (Pubitemid 39129345)
89. Feldman C., Anderson R., Theron A. J., Ramafi G., Cole P. J., Wilson R., Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro Inflammation 1997 21 6 655 665 (Pubitemid 28026335)
90. Wu L., Zhang W., Tian L., Bao K., Li P., Lin J., Immunomodulatory effects of erythromycin and its derivatives on human T-lymphocyte in vitro Immunopharmacology and Immunotoxicology 2007 29 3-4 587 596 (Pubitemid 350261187)
91. Ishida Y., Abe Y., Harabuchi Y., Effects of macrolides on antigen presentation and cytokine production by dendritic cells and T lymphocytes International Journal of Pediatric Otorhinolaryngology 2007 71 2 297 305 (Pubitemid 46054178)
92. Hiwatashi Y., Maeda M., Fukushima H., Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen Journal of Pharmacy and Pharmacology 2011 63 10 1320 1326
93. Noma T., Aoki K., Hayashi M., Yoshizawa I., Kawano Y., Effect of roxithromycin on T lymphocyte proliferation and cytokine production elicited by mite antigen International Immunopharmacology 2001 1 2 201 210 (Pubitemid 32183719)
94. Pukhalsky A. L., Shmarina G. V., Kapranov N. I., Kokarovtseva S. N., Pukhalskaya D., Kashirskaja N. J., Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease Mediators of Inflammation 2004 13 2 111 117 (Pubitemid 38698140)
95. Asano K., Kamakazu K., Hisamitsu T., Suzaki H., Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro International Immunopharmacology 2001 1 11 1913 1921 (Pubitemid 32835122)
96. Williams A. C., Galley H. F., Watt A. M., Webster N. R., Differential effects of three antibiotics on T helper cell cytokine expression Journal of Antimicrobial Chemotherapy 2005 56 3 502 506 (Pubitemid 41264127)
97. Park S. J., Lee Y. C., Rhee Y. K., Lee H. B., The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis Biochemical and Biophysical Research Communications 2004 324 1 114 117
98. Morikawa K., Zhang J., Nonaka M., Morikawa S., Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production International Journal of Antimicrobial Agents 2002 19 1 53 59 (Pubitemid 34119071)
99. Ito T., Ito N., Hashizume H., Takigawa M., Roxithromycin inhibits chemokine-induced chemotaxis of Th1 and Th2 cells but regulatory T cells Journal of Dermatological Science 2009 54 3 185 191
100. Ishimatsu Y., Kadota J. I., Iwashita T., Nagata T., Ishii H., Shikuwa C., Kaida H., Mukae H., Kohno S., Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro International Journal of Antimicrobial Agents 2004 24 3 247 253
101. Mizunoe S., Kadota J. I., Tokimatsu I., Kishi K., Nagai H., Nasu M., Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL International Immunopharmacology 2004 4 9 1201 1207 (Pubitemid 38900856)
102. Kadota J. I., Mizunoe S., Kishi K., Tokimatsu I., Nagai H., Nasu M., Antibiotic-induced apoptosis in human activated peripheral lymphocytes International Journal of Antimicrobial Agents 2005 25 3 216 220 (Pubitemid 40292751)
103. Asano K., Suzuki M., Shimane T., Suzaki H., Suppression of co-stimulatory molecule expressions on splenic B lymphocytes by a macrolide antibiotic, roxithromycin in vitro International Immunopharmacology 2001 1 7 1385 1392 (Pubitemid 32522990)
104. Aoki Y., Kao P. N., Erythromycin inhibits transcriptional activation of NF- B, but not NFAT, through calcineurin-independent signaling in T cells Antimicrobial Agents and Chemotherapy 1999 43 11 2678 2684 (Pubitemid 29519547)
105. Kanoh S., Rubin B. K., Mechanisms of action and clinical application of macrolides as immunomodulatory medications Clinical Microbiology Reviews 2010 23 3 590 615
106. Fecik R. A., Nguyen P. L., Venkatraman L., Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis Current Opinion in Drug Discovery and Development 2005 8 6 741 747 (Pubitemid 41659402)
107. Mereu A., Moriggi E., Napoletano M., Regazzoni C., Manfredini S., Mercurio T. P., Pellacini F., Design, synthesis and in vivo activity of 9-(S)-dihydroerythromycin derivatives as potent anti-inflammatory agents Bioorganic and Medicinal Chemistry Letters 2006 16 22 5801 5804 (Pubitemid 44508822)
108. Sugawara A., Sueki A., Hirose T., Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents Bioorganic Medicinal Chemistry Letters 2011 21 11 3373 3376
109. Gotfried M. H., Macrolides for the treatment of chronic sinusitis, asthma, and COPD Chest 2004 125 2, supplement 52S 61S (Pubitemid 38200961)
110. Crosbie P. A. J., Woodhead M. A., Long-term macrolide therapy in chronic inflammatory airway diseases European Respiratory Journal 2009 33 1 171 181
111. Friedlander A. L., Albert R. K., Chronic macrolide therapy in inflammatory airways diseases Chest 2010 138 5 1202 1212
112. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K., Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases European Journal of Clinical Pharmacology 2012 68 5 479 503
113. Tateda K., Ishii Y., Kimura S., Horikawa M., Miyairi S., Yamaguchi K., Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? Journal of Infection and Chemotherapy 2007 13 6 357 367 (Pubitemid 350308158)
114. Giamarellos-Bourboulis E. J., Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators International Journal of Antimicrobial Agents 2008 31 1 12 20 (Pubitemid 350236720)
115. Altenburg J., de Graaff C. S., van der Werf T. S., Boersma W. G., Immunomodulatory effects of macrolide antibioticspart 2: advantages and disadvantages of long-term, low-dose macrolide therapy Respiration 2010 81 1 75 87
116. Guillot L., Tabary O., Nathan N., Corvol H., Clement A., Macrolides: new therapeutic perspectives in lung diseases International Journal of Biochemistry and Cell Biology 2011 43 9 1241 1246
117. Nagai H., Shishido H., Yoneda R., Yamaguchi E., Tamura A., Kurashima A., Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis Respiration 1991 58 3-4 145 149
118. Kobayashi H., Ohgaki N., Takeda H., Therapeutic possibilities for diffuse panbronchiolitis International Journal of Antimicrobial Agents 1993 3 1 S81 S86
119. Koyama H., Geddes D. M., Erythromycin and diffuse panbronchiolitis Thorax 1997 52 10 915 918 (Pubitemid 27473937)
120. Kudoh S., Erythromycin treatment in diffuse panbronchiolitis Current Opinion in Pulmonary Medicine 1998 4 2 116 121 (Pubitemid 128354930)
121. Kudoh S., Azuma A., Yamamoto M., Izumi T., Ando M., Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin American Journal of Respiratory and Critical Care Medicine 1998 157 6 1829 1832
122. Yanagihara K., Kadoto J., Kohno S., Diffuse panbronchiolitispathophysiology and treatment mechanisms International Journal of Antimicrobial Agents 2001 18 1 S83 S87
123. Keicho N., Kudoh S., Diffuse panbronchiolitis: role of macrolides in therapy American Journal of Respiratory Medicine 2002 1 2 119 131 (Pubitemid 37038930)
124. Kadota J., Mukae H., Ishii H., Nagata T., Kaida H., Tomono K., Kohno S., Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis Respiratory Medicine 2003 97 7 844 850 (Pubitemid 36763898)
125. Kudoh S., Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases The American Journal of Medicine 2004 117 supplement 9 12S 19S
126. Poletti V., Chilosi M., Casoni G., Colby T. V., Diffuse panbronchiolitis Sarcoidosis Vasculitis and Diffuse Lung Diseases 2004 21 2 94 104 (Pubitemid 38954749)
127. Schultz M. J., Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and crystic fibrosis Journal of Antimicrobial Chemotherapy 2004 54 1 21 28 (Pubitemid 39028963)
128. Azuma A., Kudoh S., Diffuse panbronchiolitis in East Asia Respirology 2006 11 3 249 261
129. Poletti V., Casoni G., Chilosi M., Zompatori M., Diffuse panbronchiolitis European Respiratory Journal 2006 28 4 862 871 (Pubitemid 46332008)
130. Yang M., Dong B. R., Lu J., Lin X., Wu H. M., Macrolides for diffuse panbronchiolitis Cochrane Database of Systematic Reviews (Online) 2010 12
131. Jaff A., The anti-inflammatory effects of macrolides in cystic fibrosis Japanese Journal of Antibiotics 2001 54 supplement 77 82
132. Equi A., Balfour-Lynn I. M., Bush A., Rosenthal M., Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial The Lancet 2002 360 9338 978 984 (Pubitemid 35284109)
133. Nguyen T., Louie S. G., Beringer P. M., Gill M. A., Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease Current Opinion in Pulmonary Medicine 2002 8 6 521 528 (Pubitemid 35204705)
134. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J., Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial Thorax 2002 57 3 212 216 (Pubitemid 34214405)
135. Wolter J. M., Seeney S. L., McCormack J. G., Macrolides in cystic fibrosis: is there a role? American Journal of Respiratory Medicine 2002 1 4 235 241 (Pubitemid 37038942)
136. Saiman L., Marshall B. C., Mayer-Hamblett N., Azithromycin in patient with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial JAMA: Journal of the American Medical Association 2003 290 13 1749 1756 (Pubitemid 37430625)
137. Schni M. H., Macrolide antibiotic therapy in patients with cystic fibrosis Swiss Medical Weekly 2003 133 21-22 297 301
138. Rubin B. K., Henke M. O., Immunomodulatory activity and effectiveness of
139. Saiman L., The use of macrolide antibiotics in patients with cystic fibrosis Current Opinion in Pulmonary Medicine 2004 10 6 515 523 (Pubitemid 39441447)
140. Bell S. C., Senini S. L., McCormack J. G., Macrolides in cystic fibrosis Chronic Respiratory Disease 2005 2 2 85 98 (Pubitemid 40546607)
141. Dinwiddie R., Anti-inflammatory therapy in cystic fibrosis Journal of Cystic Fibrosis 2005 4 2, supplement 45 48 (Pubitemid 41131328)
142. Hansen C. R., Pressler T., Koch C., Hiby N., Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Journal of Cystic Fibrosis 2005 4 1 35 40 (Pubitemid 40347775)
143. Prescott W. A. Jr., Johnson G. E., Antiinflammatory therapies for cystic fibrosis: past, present, and future Pharmacotherapy 2005 25 4 555 573 (Pubitemid 40471498)
144. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., Jais J. P., Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial Thorax 2006 61 10 895 902 (Pubitemid 44570311)
145. McArdle J. R., Talwalkar J. S., Macrolides in cystic fibrosis Clinics in Chest Medicine 2007 28 2 347 360 (Pubitemid 46654478)
146. McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., Serisier D., Harris M., Bowler S., Daily versus weekly azithromycin in cystic fibrosis patients European Respiratory Journal 2007 30 3 487 495 (Pubitemid 351182072)
147. Skindersoe M. E., Alhede M., Phipps R., Yang L., Jensen P. O., Rasmussen T. B., Bjarnsholt T., Tolker-Nielsen T., Hiby N., Givskov M., Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy 2008 52 10 3648 3663
148. Steinkamp G., Schmitt-Grohe S., Dring G., Staab D., Pfrnder D., Beck G., Schubert R., Zielen S., Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection Respiratory Medicine 2008 102 11 1643 1653
149. Florescu D. F., Murphy P. J., Kalil A. C., Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis Pulmonology, Pharmacology and Therapy 2009 22 6 467 472
150. Winstanley C., Fothergill J. L., The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections FEMS Microbiology Letters 2009 290 1 1 9
151. Kabra S. K., Pawaiya R., Lodha R., Kapil A., Kabra M., Vani A. S., Agarwal G., Shastri S. S., Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial Journal of Cystic Fibrosis 2010 9 1 17 23
152. Yousef A. A., Jaffe A., The role of azithromycin in patients with cystic fibrosis Paediatric Respiratory Reviews 2010 11 2 108 114
153. Southern K. W., Barker P. M., Solis-Moya A., Patel L., Macrolide antibiotics for cystic fibrosis Cochrane Database Systematic Reviews 2011 12
154. Mikami M., Clinical and pathophysiological significance of neutrophil elastase in sputum and the effect of erythromycin in chronic respiratory diseases Nihon Kyobu Shikkan Gakkai Zasshi 1991 29 1 72 83
155. Ohgaki N., Bacterial biofilm in chronic airway infection Kansenshogaku zasshi 1994 68 1 138 151
156. Tsang K. W. T., Roberts P., Read R. C., Kees F., Wilson R., Cole P. J., The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration Journal of Antimicrobial Chemotherapy 1994 33 2 289 297 (Pubitemid 24076808)
157. Cole P. J., Brewis R. A. L., Corrin B., Geddes D. M., Gibson G. J., Bronchiectasis Respiratory Medicine 1995 2nd London, UK W. B. Saunders 1286 1317
158. Koh Y. Y., Lee M. H., Sun Y. H., Sung K. W., Chae J. H., Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study European Respiratory Journal 1997 10 5 994 999 (Pubitemid 27201800)
159. Nakamura H., Fujishima S., Inoue T., Ohkubo Y., Soejima K., Waki Y., Mori M., Urano T., Sakamaki F., Tasaka S., Ishizaka A., Kanazawa M., Yamaguchi K., Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection European Respiratory Journal 1999 13 6 1371 1379 (Pubitemid 29357155)
160. Tsang K. W. T., Ho P. I., Chan K. N., Ip M. S. M., Lam W. K., Ho C. S., Yuen K. Y., Ooi G. C., Amitani R., Tanaka E., A pilot study of low-dose erythromycin in bronchiectasis European Respiratory Journal 1999 13 2 361 364 (Pubitemid 29086834)
161. Gorrini M., Lupi A., Viglio S., Pamparana F., Cetta G., Iadarola P., Powers J. C., Luisetti M., Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics American Journal of Respiratory Cell and Molecular Biology 2001 25 4 492 499 (Pubitemid 33037682)
162. Jaff A., Bush A., Anti-inflammatory effects of macrolides in lung disease Pediatric Pulmonology 2001 31 6 464 473 (Pubitemid 32523640)
163. Shibuya Y., Wills P. J., Cole P. J., The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum Respiration 2001 68 6 615 619 (Pubitemid 34062936)
164. Tagaya E., Tamaoki J., Kondo M., Nagai A., Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion Chest 2002 122 1 213 218 (Pubitemid 34754165)
165. Bush A., Rubin B. K., Macrolides as biological response modifiers in cystic fibrosis and bronchiectasis Seminars in Respiratory and Critical Care Medicine 2003 24 6 737 747 (Pubitemid 38036768)
166. Davies G., Wilson R., Prophylactic antibiotic treatment of bronchiectasis with azithromycin Thorax 2004 59 6 540 541 (Pubitemid 38797534)
167. Cymbala A. A., Edmonds L. C., Bauer M. A., Jederlinic P. J., May J. J., Victory J. M., Amsden G. W., The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis Treatments in Respiratory Medicine 2005 4 2 117 122 (Pubitemid 40613959)
168. Miz Carro L., Long-term treatment with azithromycin in a patient with idiopathic bronchiectasis Archivos de Bronconeumologia 2005 41 5 295
169. Verleden G. M., Dupont L. J., Vanhaecke J., Daenen W., Van Raemdonck D. E. M., Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report Journal of Heart and Lung Transplantation 2005 24 8 1155 1158 (Pubitemid 41127211)
170. Yalcin E., Kiper N., Ozcelik U., Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis Journal of Clinical Pharmacology and Therapeutics 2006 31 1 49 55
171. Vila-Justribo M., Dorca-Sargatal J., Bello-Dronda S., Bronchiectasis and macrolides Archivos de Bronconeumologia 2006 42 4 206
172. King P., Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 2007 67 7 965 974 (Pubitemid 46744473)
173. Anwar G. A., Bourke S. C., Afolabi G., Middleton P., Ward C., Rutherford R. M., Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis Respiratory Medicine 2008 102 10 1494 1496
174. Tsang K. W., Bilton D., Clinical challenges in managing bronchiectasis series Respirology 2009 14 5 637 650
175. Metersky M. L., New treatment options for bronchiectasis Therapeutic Advances in Respiratory Disease 2010 4 2 93 99
176. Bochet M., Garin N., Janssens J. P., Gerstel E., Is there a role for prophylactic antibiotic treatment with macrolides in bronchiectasis? Revue Medicale Suisse 2011 7 280 308 312
177. Serisier D. J., Martin M. L., Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations Respiratory Medicine 2011 105 6 946 949
178. Gerhardt S. G., McDyer J. F., Girgis R. E., Conte J. V., Yang S. C., Orens J. B., Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study American Journal of Respiratory and Critical Care Medicine 2003 168 1 121 125 (Pubitemid 37046642)
179. Verleden G. M., Dupont L. J., Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation Transplantation 2004 77 9 1465 1467 (Pubitemid 38668447)
180. Crowley S., Egan J. J., Macrolide antibiotics and bronchiolitis obliterans following lung transplantation Expert Review of Anti-Infective Therapy 2005 3 6 923 930 (Pubitemid 41782593)
181. Yates B., Murphy D. M., Forrest I. A., Ward C., Rutherford R. M., Fisher A. J., Lordan J. L., Dark J. H., Corris P. A., Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome American Journal of Respiratory and Critical Care Medicine 2005 172 6 772 775 (Pubitemid 41324235)
182. Fietta A. M., Meloni F., Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome Current Medicinal Chemistry 2008 15 7 716 723 (Pubitemid 351516807)
183. Gottlieb J., Szangolies J., Koehnlein T., Golpon H., Simon A., Welte T., Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation Transplantation 2008 85 1 36 41
184. Porhownik N. R., Batobara W., Kepron W., Unruh H. W., Bshouty Z., Effect of maintenance azithromycin on established bronchiolits obliterans syndrome in lung transplant patients Canadian Respiratory Journal 2008 15 4 199 202
185. Vanaudenaerde B. M., Meyts I., Vos R., Geudens N., De Wever W., Verbeken E. K., Van Raemdonck D. E., Dupont L. J., Verleden G. M., A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy European Respiratory Journal 2008 32 4 832 843
186. Benden C., Boehler A., Long-term clarithromycin therapy in the management of lung transplant recipients Transplantation 2009 87 10 1538 1540
187. Maimon N., Lipton J. H., Chan C. K. N., Marras T. K., Macrolides in the treatment of bronchiolitis obliterans in allograft recipients Bone Marrow Transplantation 2009 44 2 69 73
188. Jain R., Hachem R. R., Morrell M. R., Trulock E. P., Chakinala M. M., Yusen R. D., Huang H. J., Mohanakumar T., Patterson G. A., Walter M. J., Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome Journal of Heart and Lung Transplantation 2010 29 5 531 537
189. Vos R., Vanaudenaerde B. M., Ottevaere A., Verleden S. E., De Vleeschauwer S. I., Willems-Widyastuti A., Wauters S., Van Raemdonck D. E., Nawrot T. S., Dupont L. J., Verleden G. M., Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? Journal of Heart and Lung Transplantation 2010 29 12 1358 1368
190. Fisher A. J., Azithromycin and bronchiolitis obliterans syndrome after lung transplantation: is prevention better than cure? European Respiratory Journal 2011 37 1 10 12
191. Vos R., Vanaudenaerde B. M., Verleden S. E., De Vleeschauwer S. I., Willems-Widyastuti A., Van Raemdonck D. E., Schoonis A., Nawrot T. S., Dupont L. J., Verleden G. M., A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation European Respiratory Journal 2011 37 1 164 172
192. Tamaoki J., Takeyama K., Tagaya E., Konno K., Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections Antimicrobial Agents and Chemotherapy 1995 39 8 1688 1690
193. Swords W. E., Rubin B. K., Macrolide antibiotics, bacterial populations and inflammatory airway disease The Netherlands Journal of Medicine 2003 61 7 242 248 (Pubitemid 39089409)
194. Banerjee D., Honeybourne D., Khair O. A., The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial Treatments in Respiratory Medicine 2004 3 1 59 65 (Pubitemid 38444332)
195. Basyigit I., Yildiz F., Ozkara S. K., Yildirim E., Boyaci H., Ilgazli A., The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data Annals of Pharmacotherapy 2004 38 9 1400 1405 (Pubitemid 39100191)
196. Barnes P. J., Mediators of chronic obstructive pulmonary disease Pharmacological Reviews 2004 56 4 515 548 (Pubitemid 39658462)
197. Banerjee D., Khair O. A., Honeybourne D., The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD Respiratory Medicine 2005 99 2 208 215 (Pubitemid 40104276)
198. Bishai W. R., Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin Expert Review of Anti-Infective Therapy 2006 4 3 405 416 (Pubitemid 43905463)
199. Murphy D. M., Forrest I. A., Curran D., Ward C., Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects? Expert Opinion on Investigational Drugs 2010 19 3 401 414
200. Amayasu H., Yoshida S., Ebana S., Yamamoto Y., Nishikawa T., Shoji T., Nakagawa H., Hasegawa H., Nakabayashi M., Ishizaki Y., Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma Annals of Allergy, Asthma and Immunology 2000 84 6 594 598 (Pubitemid 30418859)
201. Cazzola M., Salzillo A., Diamare F., Potential role of macrolides in the treatment of asthma Monaldi Archives for Chest Disease 2000 55 3 231 236 (Pubitemid 30636147)
202. Ekici A., Ekici M., Kemal Erdemolu A., Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma Journal of Asthma 2002 39 2 181 185 (Pubitemid 34464576)
203. Beuther D. A., Martin R. J., Antibiotics in asthma Current Allergy and Asthma Reports 2004 4 2 132 138 (Pubitemid 38906754)
204. Hatipolu U., Rubinstein I., Low-dose, long-term macrolide therapy in asthma: an overview Clinical and Molecular Allergy 2004 2 1, article 4
205. Kostadima E., Tsiodras S., Alexopoulos E. I., Kaditis A. G., Mavrou I., Georgatou N., Papamichalopoulos A., Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma European Respiratory Journal 2004 23 5 714 717 (Pubitemid 38618141)
206. Ferrara G., Losi M., Franco F., Corbetta L., Fabbri L. M., Richeldi L., Macrolides in the treatment of asthma and cystic fibrosis Respiratory Medicine 2005 99 1 1 10 (Pubitemid 40017377)
207. Richeldi L., Ferrara G., Fabbri L. M., Lasserson T. J., Gibson P. G., Macrolides for chronic asthma Cochrane Database of Systematic Reviews (Online) 2005 4 3
208. Richeldi L., Ferrara G., Fabbri L. M., Lasserson T. J., Gibson P. G., Macrolides for chronic asthma Cochrane Database of Systematic Reviews (Online) 2005 3
209. Black P. N., Antibiotics for the treatment of asthma Current Opinion in Pharmacology 2007 7 3 266 271 (Pubitemid 46744830)
210. Sharma S., Jaffe A., Dixon G., Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis Pediatric Drugs 2007 9 2 107 118 (Pubitemid 46624563)
211. Hernando-Sastre V., Macrolide antibiotics in the treatment of asthma. An update Allergologia et Immunopathologia 2010 38 2 92 98
212. Rollins D. R., Beuther D. A., Martin R. J., Update on infection and antibiotics in asthma Current Allergy and Asthma Reports 2010 10 1 67 73
213. Oliveinstein R., Jahdali H. A., Alkhamis N., Halwani R., Al-Muhsen S., Hamid Q., Challenges in the management of severe asthma: role of current and future therapies Current Pharmaceutical Design 2011 17 7 703 711
214. Good J. T. Jr., Rollins D. R., Martin R. J., Macrolides in the treatment of asthma Current Opinion in Pulmonary Medicine 2012 18 1 76 84
215. Gleason P. P., Meehan T. P., Fine J. M., Galusha D. H., Fine M. J., Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia Archives of Internal Medicine 1999 159 21 2562 2572
216. Waterer G. W., Somes G. W., Wunderink R. G., Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia Archives of Internal Medicine 2001 161 15 1837 1842 (Pubitemid 32762726)
217. Brown R. B., Iannini P., Gross P., Kunkel M., Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database Chest 2003 123 5 1503 1511 (Pubitemid 36549769)
218. Martinez J. A., Horcajada J. P., Almela M., Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia Clinical Infectious Diseases 2003 36 4 389 395 (Pubitemid 36241302)
219. Baddour L. M., Yu V. L., Klugman K. P., Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia American Journal of Respiratory and Critical Care Medicine 2004 170 4 440 444 (Pubitemid 39214620)
220. Mortensen E. M., Restrepo M. I., Anzueto A., Pugh J., The impact of empiric antimicrobial therapy with a -lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia Critical Care 2005 10 1, article R8
221. Metersky M. L., Ma A., Houck P. M., Bratzler D. W., Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones Chest 2007 131 2 466 473 (Pubitemid 46280407)
222. Rodriguez A., Mendia A., Sirvent J. M., Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock Critical Care Medicine 2007 35 6 1493 1498 (Pubitemid 46809312)
223. Feldman C., Anderson R., Therapy for pneumococcal bacteremia: monotherapy or combination therapy? Current Opinion in Infectious Diseases 2009 22 2 137 142
224. Restrepo M. I., Mortensen E. M., Waterer G. W., Wunderink R. G., Coalson J. J., Anzueto A., Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia European Respiratory Journal 2009 33 1 153 159
225. Tessmer A., Welte T., Martus P., Schnoor M., Marre R., Suttorp N., Impact of intravenous -lactam/macrolide versus -lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia Journal of Antimicrobial Chemotherapy 2009 63 5 1025 1033
226. Martin-Loeches I., Lisboa T., Rodriguez A., Putensen C., Annane D., Garnacho-Montero J., Restrepo M. I., Rello J., Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia Intensive Care Medicine 2010 36 4 612 620
227. Bratzler D. W., Ma A., Nsa W., Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project Clinical Infectious Diseases 2008 47 S193 201
228. Torres A., Garau J., Arvis P., Carlet J., Choudhri S., Kureishi A., Le Berre M. A., Lode H., Winter J., Read R. C., Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV studya randomized clinical trial Clinical Infectious Diseases 2008 46 10 1499 1509 (Pubitemid 351706729)
229. Ewig S., Hecker H., Suttorp N., Marre R., Welte T., Moxifloxacin monotherapy versus -lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia Journal of Infection 2011 62 3 218 225
230. Epstein B. J., Gums J. G., Optimal pharmacological therapy for community-acquired pneumonia the role of dual antibacterial therapy Drugs 2005 65 14 1949 1971 (Pubitemid 41324057)
231. Giamarellos-Bourboulis E. J., Pechre J. C., Routsi C., Plachouras D., Kollias S., Raftogiannis M., Zervakis D., Baziaka F., Koronaios A., Antonopoulou A., Markaki V., Koutoukas P., Papadomichelakis E., Tsaganos T., Armaganidis A., Koussoulas V., Kotanidou A., Roussos C., Giamarellou H., Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia Clinical Infectious Diseases 2008 46 8 1157 1164 (Pubitemid 351589897)
232. Kovaleva A., Remmelts H. H. F., Rijkers G. T., Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review Journal of Antimicrobial Chemotherapy 2012 67 3 5305 540
233. Walkey A. J., Wiener R. S., Macrolide antibiotics and survival in patients with acute lung injury Chest 2012 141 5 1153 1159
234. Cervin A., The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis Acta Oto-Laryngologica 2001 121 1 83 92 (Pubitemid 32205030)
235. Suzuki H., Ikeda K., Mode of action of long-term low-dose macrolide therapy for chronic sinusitis in the light of neutrophil recruitment Current Drug TargetsInflammation Allergy 2002 1 1 117 126
236. Garey K. W., Alwani A., Danziger L. H., Rubinstein I., Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases Chest 2003 123 1 261 265 (Pubitemid 36126738)
237. Majima Y., Clinical implications of the immunomodulatory effects of macrolides on sinusitis The American Journal of Medicine 2004 117 supplement 9 20S 25S
238. Cervin A., Wallwork B., Anti-inflammatory effects of macrolide antibiotics in the treatment of chronic rhinosinusitis Otolaryngologic Clinics of North America 2005 38 6 1339 1350 (Pubitemid 41737842)
239. Hatipoglu U., Rubinstein I., Treatment of chronic rhinosinusitis with low-dose, long-term macrolide antibiotics: an evolving paradigm Current Allergy and Asthma Reports 2005 5 6 491 494 (Pubitemid 41683974)
240. Wallwork B., Coman W., Mackay-Sim A., Greiff L., Cervin A., A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis Laryngoscope 2006 116 2 189 193 (Pubitemid 44383921)
241. Cervin A., Wallwork B., Macrolide therapy of chronic rhinosinusitis Rhinology 2007 45 4 259 267
242. Harvey R. J., Wallwork B. D., Lund V. J., Anti-inflammatory effects of macrolides: applications in chronic rhinosinusitis Immunology and Allergy Clinics of North America 2009 29 4 689 703
243. Meltzer E. O., Hamilos D. L., Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines Mayo Clinic Proceedings 2011 86 5 427 443
244. Piromchai P., Thanaviratananich S., Laopaiboon M., Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults Cochrane Database of Systematic Reviews (Online) 2011 5